Neuralstem Hanging on as Investors Lose Interest

Neuralstem, Inc. (NYSEAMEX:CUR) investors will have noted the biotech company's slow share decline this year. From September 2011's high of $1.52, shares took an ambling 56% descent to Tuesday's closing price of $0.66. As of mid-day Wednesday, shares are off by 21%. The gradual decline, with brief rallies in February and July, has left many scratching their heads. The company is built on stem cell technology, with a candidate in Phase I/II trials for the treatment of Amyotrophic Lateral Sclerosis (ALS), with further stem cell programs in oncology and drug treatments in clinical trials for depression.